Why a cancer of the immune system often hides in your bones
In short: Multiple myeloma is a blood cancer that originates in plasma cells, the white blood cells responsible for producing antibodies. Instead of circulating freely, these cancerous cells accumulate in the bone marrow, where they produce abnormal proteins that can damage organs and weaken the skeletal structure from the inside out.
Multiple myeloma is a malignant condition where plasma cells—the immune system's antibody factories—undergo a transformation. Rather than performing their protective role, these cells proliferate in the bone marrow, the spongy tissue responsible for blood cell production. This process is rarely sudden; it is almost universally preceded by a pre-malignant stage known as monoclonal gammopathy of undetermined significance (MGUS). In this early phase, patients exhibit low levels of monoclonal proteins without organ damage. As the condition progresses, it may transition into smoldering multiple myeloma, a state where abnormal cells are present but have not yet triggered clinical symptoms or organ failure.
The clinical impact of the disease is largely driven by the accumulation of these abnormal plasma cells and the proteins they secrete. These proteins, often called M proteins, can overwhelm the kidneys, leading to potential failure. Simultaneously, the growth of myeloma cells within the marrow disrupts normal blood cell production, frequently resulting in anemia. Perhaps most visibly, the disease causes significant bone issues. Over 80% of patients present with bone damage at diagnosis, as the cancer cells trigger bone thinning and fractures, particularly in the spine, hips, and skull. This bone breakdown also releases calcium into the bloodstream, causing hypercalcemia, which manifests as confusion, nausea, and extreme thirst.
While the exact cause remains unknown, the disease involves complex genetic changes within the plasma cells. Risk factors include advancing age, with a median diagnosis age of about 65, and a family history of the condition. In the United States, Black individuals are statistically more likely to develop the disease than white individuals. Although multiple myeloma is generally considered incurable, it is highly treatable. Modern therapeutic approaches, including chemotherapy, steroids, targeted therapies, stem cell transplants, and emerging CAR-T cell treatments, aim to control the disease, manage complications like infections, and improve the patient's quality of life.
The diagnostic process typically involves blood or urine tests to detect the presence of monoclonal proteins, often identified as an m-spike, alongside bone marrow biopsies and medical imaging to locate bone lesions. Because the disease impairs the immune system's ability to resist pathogens, patients face a heightened risk of infections, particularly in the months following the initiation of new drug therapies. Despite these challenges, ongoing advancements in clinical management are helping patients live longer, shifting the focus toward long-term maintenance and symptom control.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Multiple myeloma - Symptoms and causes
- Also: Multiple myeloma
To cite this card, link to https://intellectplus.co.uk/app/history-multiple-myeloma.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Modern · More in History · Latest · A–Z · All topics